Shares of Applied Therapeutics plunged in premarket trading on January 3 after the company announced it is unable to seek regulatory approval of the Galactosemia therapeutic AT-007 at this time.

The Covid-19 vaccine developed by Pfizer and BioNTech is effective at preventing symptomatic and severe disease in people with some chronic illnesses, like diabetes and heart disease, the biggest real-world study showed on April 22.

Anima Biotech’s strategic collaboration with Takeda Pharmaceutical uses its novel platform for discovery of mRNA translation modulators to discover and develop a new class of therapies for neurological diseases.

The U.S. Food and Drug Administration approved Pfizer Inc.’s supplemental Biologics License Application for Panzyga to treat adult patients with a rare neurological disease of the peripheral nerves called chronic inflammatory demyelinating polyneuropathy (CIDP).

Shares of Voyager Therapeutics dropped more than 12 percent as investors reacted negatively to an announcement that Neurocrine Biosciences is terminating a Parkinson’s disease collaboration between the two companies.

France-based Servier and U.K.-based MiNA Therapeutics are partnering on small activating RNA (saRNA) therapies to treat neurological diseases

Switzerland-based Noema Pharma raised $59 million in a Series A financing round that will support the development of four clinical-stage assets the company licensed from Roche for the treatment of orphan neurological diseases with severe unmet needs.

UCB is investing more than £1 billion ($1.29 billion) over five years to expand the company’s research and development capabilities in the U.K., which will include a transition to a newly acquired 47-acre R&D campus from Eli Lilly located in Windlesham, Surrey.

South San Francisco-based Unity Biotechnology reported that the 12-week results from the company’s Phase II study of UBX0101 in moderate-to-severe painful osteoarthritis (OA) of the knee failed to show improvement over placebo.

The investigational multiple sclerosis drug ofatumumab cut the relapse rate in patients by more than half in clinical trials compared to Sanofi’s Aubagio as Novartis aims to refresh the Swiss drugmaker’ portfolio of medicines in neurological diseases.